Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart

Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart on March 24, 2026.

Rhea-AI Summary

Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart on March 24, 2026. The OTC hydrogel is indicated for minor burns and skin irritations and is marketed via a U.S.-based distribution partner.

This is Sonoma's first large-scale consumer burn product, following its 2025 diaper rash hydrogel retail rollout, and complements the company's professional wound and burn care portfolio while leveraging strategic partnerships for mass‑market distribution.

Argus Mar 24 session

-8.24% close to close Open Argus

Details

News Market Reaction – SNOA

In the Mar 24 session, SNOA declined 8.24%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -8.2% in the session following this news. A negative reaction despite a retail launc...

Analysis

The stock moved -8.2% in the session following this news. A negative reaction despite a retail launch would fit a pattern where some positive dermatology milestones, like past product endorsements, did not consistently translate into share gains. Recent 10-Q disclosures cited recurring losses and going-concern risks, so investors may have focused on balance-sheet pressure rather than incremental OTC expansion. In a thinly capitalized name near $4.2M market value, modest order visibility or execution concerns could have led to outsized downside swings.

Historical Context

5 past events · Latest: Mar 18

5 events

1. Mar 18

   OTC line launch

   24h Move

   +2.9%

   Launch of Aquanil AD HOCl dermatology products for sensitive skin OTC.

2. Feb 10

   Earnings update

   24h Move

   +1.4%

   Q3 FY26 revenue and margin growth with improved EBITDAS loss.

3. Jan 28

   Leadership changes

   24h Move

   -1.5%

   Board refresh and new SVP of Regulatory, Quality and Product Development.

4. Nov 13

   Dermatology endorsement

   24h Move

   -3.8%

   Reliefacyn hydrogel earned National Rosacea Society Seal of Acceptance.

5. Nov 06

   Conference exhibit

   24h Move

   +0.8%

   Participation at MEDICA 2025 showcasing HOCl-based scar and skin products.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

hypochlorous acid, hocl, hydrogel

3 terms

hypochlorous acid medical

"glo bal healthcare leader in hypochlorous acid (HOCl) technology, today announced"

A mild, naturally occurring chemical formed when chlorine dissolves in water that acts as a fast-acting disinfectant and antiseptic. Think of it like a gentle, short-lived version of bleach that kills bacteria and viruses without strong fumes or persistent chemical residue. Investors watch it because demand, regulatory approvals, production capacity and safety perceptions directly affect sales in cleaning, healthcare and water-treatment markets, influencing product lines and revenue.

hocl medical

"global healthcare leader in hypochlorous acid (HOCl) technology, today announced"

Hypochlorous acid (HOCl) is a weak, fast‑acting disinfectant chemical that is produced by the immune system and formulated for use in wound care, surface sanitizers, and medical devices. Investors watch HOCl products because their safety profile, regulatory approvals, and manufacturing scalability determine how widely they can replace harsher cleaners or be adopted in healthcare and consumer markets — think of it as a gentler, quick‑acting sanitizer that can open or close market opportunities.

hydrogel medical

"retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart"

A hydrogel is a soft, jelly-like material made mostly of water combined with a network of flexible, supportive molecules. Its unique ability to hold large amounts of water while remaining stable makes it useful in various medical, industrial, and consumer applications. For investors, innovations involving hydrogels can signal growth opportunities in sectors like healthcare, biotechnology, and advanced materials.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS and Walmart stores nationwide.

The hydrogel is indicated for the management of minor burns and skin irritations. Its gentle, non-irritating formulation is designed to help soothe damaged skin and support the natural healing process, making it well-suited for everyday consumer use, including seasonal sunburn care.

This launch represents Sonoma's first large-scale consumer-focused burn relief product, building on the Company's established presence in professional healthcare settings, where its HOCl-based solutions have long been used in advanced wound and burn care protocols. Sonoma previously demonstrated its ability to translate clinically proven technologies into scalable consumer offerings through the launch of its diaper rash hydrogel in mass retail in 2025.

The product is being commercialized through one of Sonoma's U.S.-based partners that distributes through CVS and Walmart, in line with the Company's strategy to leverage strategic partnerships to expand its presence across major retail channels while maintaining focus on innovation, regulatory compliance, and manufacturing excellence.

"We are excited to expand further into the consumer over-the-counter market with the introduction of our advanced burn relief hydrogel in leading U.S. retailers," said Amy Trombly, Chief Executive Officer of Sonoma Pharmaceuticals. "This launch builds on the strong foundation established by our prior consumer product success and reflects growing consumer awareness of hypochlorous acid as a safe and effective skincare solution. We believe this product is well-positioned to meet increasing demand for clinically-backed, gentle solutions for everyday skin concerns."

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare company focused on developing and manufacturing stabilized hypochlorous acid (HOCl) products for medical, veterinary, and consumer applications. The Company's patented HOCl technology platform is designed to provide safe, effective, and environmentally friendly solutions for a wide range of indications, including wound care, dermatological conditions, and burn treatment. With integrated custom packaging and branding capabilities and multi-country regulatory expertise, Sonoma supports distribution partners in 55 countries worldwide and is actively expanding its global distributor network. The company's principal office is in Boulder, Colorado, with high-capacity manufacturing operations in Guadalajara, Mexico, and European commercial headquarters in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, the ability to meet a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™ and Microcyn^® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
ir@sonomapharma.com

Website: www.sonomapharma.com

Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals

Follow us on Instagram: https://www.instagram.com/sonomapharma_us/

Follow us on Facebook: https://www.facebook.com/sonomapharma/

SOURCE: Sonoma Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Sonoma Pharmaceuticals (SNOA) launching in CVS and Walmart on March 24, 2026?

Sonoma is launching an advanced HOCl-based burn relief hydrogel for minor burns and skin irritations. According to the company, the OTC product is positioned for everyday consumer use, including seasonal sunburn care, and will be distributed through a U.S.-based retail partner.

How is the SNOA burn relief hydrogel being distributed to U.S. consumers?

The product is being commercialized through a U.S.-based partner that supplies CVS and Walmart nationwide. According to the company, this partnership leverages established retail channels to scale consumer availability across major stores.

What medical uses does the Sonoma (SNOA) burn relief hydrogel serve?

The hydrogel is indicated for management of minor burns and skin irritations and to support natural healing. According to the company, its gentle, non-irritating HOCl formulation is intended for everyday topical relief, including sunburn care.

How does the new SNOA retail launch relate to Sonoma's prior consumer products?

This launch follows Sonoma's 2025 mass-retail diaper rash hydrogel and reflects repeat consumer commercialization. According to the company, the new burn product builds on prior success translating clinical HOCl technology into scalable consumer offerings.

What does Sonoma say about the strategic importance of the March 24, 2026 retail launch for SNOA shareholders?

Sonoma describes the launch as expansion into the over-the-counter consumer market via major retailers. According to the company, this supports its strategy of using partnerships to increase retail presence while focusing on innovation and regulatory compliance.